Long-term darifenacin treatment for overactive bladder in patients aged 65 years and older: Analysis of results from a 2-year, open-label extension study

Current Medical Research and Opinion

Volumn 23, Issue 11, 2007, Pages 2697-2704

  Hill, Simon ^a   Elhilali, Mostafa ^b   Millard, Richard J ^c   Dwyer, Peter L ^d   Lheritier, Karine ^e   Kawakami, Fernando T ^e   Steel, Michael ^e  

^a ROYAL BLACKBURN HOSPITAL   (United Kingdom)

^b MCGILL UNIVERSITY   (Canada)

^c PRINCE OF WALES HOSPITAL   (Australia)

^d MERCY HOSPITAL FOR WOMEN   (Australia)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Antimuscarinic; Darifenacin; Elderly; Long term treatment; Overactive bladder

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DARIFENACIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MUSCARINIC M3 RECEPTOR ANTAGONIST; PLACEBO;

AGED; ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELDERLY CARE; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MICTURITION; OVERACTIVE BLADDER; PATIENT COMPLIANCE; SUSTAINED DRUG RELEASE; TREATMENT OUTCOME; XEROSTOMIA;

AGED; AGED, 80 AND OVER; BENZOFURANS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MUSCARINIC ANTAGONISTS; PLACEBOS; PYRROLIDINES; URINARY BLADDER, OVERACTIVE;

EID: 36348964213     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X233160     Document Type: Article

References (34)

1. Andersson K-E, Appell R, Awad S, et al. Pharmacological treatment of urinary incontinence. In: Abrams P, Khoury S, Wein A, editors. Incontinence, 2nd international consultation on incontinence. Plymouth: Plymbridge Distributors Ltd; 2002. p. 480-511
2. Yamanishi T, Chapple CR, Chess-Williams R. Which muscarinic receptor is important in the bladder? World J Urol 2001;19:299-306
3. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. Br J Urol Int 2001;87:760-6 [erratum 2001;88:807]
4. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36
5. Haferkamp A, Elbadawi A. Ultrastructural changes in the aging bladder. Urologe A 2004;43:527-34 [German]
6. Tune L, Carr S, Hoag E, Cooper T. Anticholinergic effects of drugs commonly prescribed for the elderly: potential means for assessing risk of delirium. Am J Psychiatry 1992;149:1393-4
7. Staskin DR. Overactive bladder in the elderly: a guide to pharmacological management. Drugs Aging 2005;22:1013-28
8. 3 receptor selectivity. Eur Urol Suppl 2002;1:23-8
9. 3 selective receptor antagonist. Eur Urol 2005;48:471-7
10. Malone-Lee JG, Walsh JB, Maugourd M-F, et al. Tolterodine: a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc 2001;49:700-5
11. Zinner NR, Mattiasson A, Stanton SL. Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients. J Am Geriatr Soc 2002;50:799-807
12. Zorzitto ML, Holliday PJ, Jewett MAS, et al. Oxybutynin chloride for geriatric urinary dysfunction: a double-blind placebo-controlled study. Age Ageing 1989;18:195-200
13. Szonyi G, Collas Dm, Ding YY, et al. Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial. Age Ageing 1995;24:287-91
14. Wagg A, Wyndaele JJ, Sieber P. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis. Am J Geriatr Pharmacother 2006;4:14-24
15. Abrams P, Malone-Lee J, Jacquetin B, et al. Twelve-month treatment of overactive bladder: efficacy and tolerability of tolterodine. Drugs Aging 2001;18:551-60
16. Diokno A, Sand P, Labasky R, et al. Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: a one-year study. Int Urol Nephrol 2002;34:43-9
17. Kreder K, Mayne C, Jonas U. Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. Eur Urol 2002;41:588-95
18. Halaska M, Ralph G, Wiedemann A, et al. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 2003;20:392-9
19. Haab F, Corcos J, Siami P, et al. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. Br J Urol Int 2006;98:1025-32
20. 3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 2004;45:420-9
21. 3 selective receptor antagonist. Br J Urol Int 2005;95:580-6 [erratum 2005;95:1385-6]
22. Zinner N, Gittelman M, Harris R, et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol 2004;171:2311-5
23. Szonyi G, Collas DM, Ding YY, Malone-Lee JG. Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial. Age Ageing 1995;24:287-91
24. Malone-Lee JG, Walsh JB, Maugourd MF. Tolterodine: a safe and effective treatment for older patients with overactive bladder. J Am Geriatr Soc 2001;49:700-5
25. Haab F, Cardozo L, Chapple C, Ridder AM; Solifenacin Study Group. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol 2005;47:376-84
26. Salvatore S, Khullar V, Cardozo L, et al. Long-term prospective randomized study comparing two different regimens of oxybutynin as a treatment for detrusor overactivity. Eur J Obstet Gynecol Reprod Biol 2005;119:237-41
27. Lawrence M, Guay DR, Benson SR, Anderson MJ. Immediate-release oxybutynin versus tolterodine in detrusor overactivity: a population analysis. Pharmacotherapy 2000;20:470-5
28. Ouslander JG, Shih YT, Malone-Lee J, Luber K. Overactive bladder: special considerations in the geriatric population. Am J Manag Care 2000;6(Suppl 11):S599-S606
29. 3 receptor subtype [abstract]. As presented at the International Continence Society 2002, Heidelberg, Germany as a non-discussion poster abstract. A445. Available at http://www.icsoffice.org/publications/2002/PDF/445. PDF [last accessed 24 May 2007]
30. 3 selective receptor antagonist for the treatment of overactive bladder. J Clin Pharmacol 2005;45:1038-47
31. Kay GG, Abou-Donia MB, Messer Jr WS, et al. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc 2005;53:2195-201
32. Kay G, Crook T, Rekeda L, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol 2006;50:317-26
33. Lipton RB, Kolodner K, Wesnes K. Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol 2005;173:493-8
34. Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 2006;148:565-78